Meeting
2015 Genitourinary Cancers Symposium
Survival comparison analysis of two historical cohorts of metastatic renal cell carcinoma patients (cytokine therapy versus targeted agents): A European single-center experience over 26 years.
Authors
Georg C. Hutterer
Department of Urology, Medical University of Graz, Graz, Austria
Georg C. Hutterer , Silvia V. Golbeck , Edvin Mrsic , Daniel Krieger , Angelika Bezan , Johanna Jesche , Karl Pummer , Richard Zigeuner , Martin Pichler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 513)
DOI
10.1200/jco.2015.33.7_suppl.513
Abstract #
513
Poster Bd #
H25
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
First Author: E. Jason Abel
Poster
2020 Genitourinary Cancers Symposium
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
First Author: Joseph Miccio
Poster
2019 Genitourinary Cancers Symposium
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).
First Author: Aly-Khan A. Lalani
Poster
2016 ASCO Annual Meeting
Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.
First Author: Joseph Clark